Paper Details

  1. Home
  2. Paper Details

Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.

Author: AbdulkhakovSayar, AlekseevaOlga, AndreevPavel, DatsenkoOleksii, DorofeyevAndrey E, GreinwaldRoland, KruisWolfgang, LevchenkoOlena, LozynskyyYuriy, MohrbacherRalf, MostovoyYuriy, NeshtaViacheslav, PesegovaMarina, SiegmundBritta, SolovievKonstantin, StiessMichael, ViethMichael

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the efficacy and safety of budesonide and mesalamine suppositories for treating proctitis.
Paper Details　
Original Abstract of the Article :
Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine sup...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cgh.2018.04.027

データ提供：米国国立医学図書館（NLM）

Budesonide Suppositories: An Effective and Safe Treatment for Ulcerative Proctitis

Ulcerative proctitis, a localized form of ulcerative colitis, can cause significant discomfort and impact quality of life. This randomized phase 2 trial aimed to evaluate the efficacy and safety of budesonide suppositories, compared to mesalamine suppositories and a combination of both, for treating ulcerative proctitis. The researchers recruited patients and randomly assigned them to receive one of the three treatment regimens. Their analysis showed that budesonide suppositories were effective in reducing symptoms of ulcerative proctitis and were well-tolerated by patients.

A New Option for Treating Ulcerative Proctitis

This research presents budesonide suppositories as a promising new treatment option for ulcerative proctitis. The findings suggest that budesonide can effectively alleviate symptoms and may be a valuable alternative for patients who do not respond well to mesalamine therapy.

Tailoring Treatment: A Personalized Approach to IBD

This study emphasizes the importance of individualized treatment strategies for inflammatory bowel diseases (IBD). The efficacy of budesonide in treating ulcerative proctitis suggests that different treatment modalities may be more effective for specific manifestations of IBD. This highlights the need for a personalized approach to IBD management, considering the individual patient's disease characteristics and response to therapy.

Dr.Camel's Conclusion

Just as a desert traveler needs a reliable source of water to survive, patients with ulcerative proctitis need effective treatment options. This study offers hope for those struggling with this condition, presenting budesonide suppositories as a potentially valuable addition to the therapeutic arsenal. By understanding the individual needs of each patient, we can navigate the challenges of IBD and strive for improved outcomes and a better quality of life.

Date :
  1. Date Completed 2020-01-29
  2. Date Revised 2020-01-29
Further Info :

Pubmed ID

29702300

DOI: Digital Object Identifier

10.1016/j.cgh.2018.04.027

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.